Longitudinal tracking of FTLD

Toward developing clinical trial methodology

David S Knopman, Bradley F Boeve, Richard John Caselli, Neill R Graff Radford, Joel H. Kramer, Mario F. Mendez, Bruce L. Miller

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

Original languageEnglish (US)
JournalAlzheimer Disease and Associated Disorders
Volume21
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Frontotemporal Lobar Degeneration
Clinical Trials
Multicenter Studies
Longitudinal Studies
Biomarkers

Keywords

  • Clinical trials
  • Frontotemporal lobar degeneration
  • Longitudinal studies
  • Primary progressive aphasia

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Longitudinal tracking of FTLD : Toward developing clinical trial methodology. / Knopman, David S; Boeve, Bradley F; Caselli, Richard John; Graff Radford, Neill R; Kramer, Joel H.; Mendez, Mario F.; Miller, Bruce L.

In: Alzheimer Disease and Associated Disorders, Vol. 21, No. 4, 10.2007.

Research output: Contribution to journalArticle

@article{48a856178d9d42259b34bdd256a399b6,
title = "Longitudinal tracking of FTLD: Toward developing clinical trial methodology",
abstract = "Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.",
keywords = "Clinical trials, Frontotemporal lobar degeneration, Longitudinal studies, Primary progressive aphasia",
author = "Knopman, {David S} and Boeve, {Bradley F} and Caselli, {Richard John} and {Graff Radford}, {Neill R} and Kramer, {Joel H.} and Mendez, {Mario F.} and Miller, {Bruce L.}",
year = "2007",
month = "10",
doi = "10.1097/WAD.0b013e31815bf69d",
language = "English (US)",
volume = "21",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Longitudinal tracking of FTLD

T2 - Toward developing clinical trial methodology

AU - Knopman, David S

AU - Boeve, Bradley F

AU - Caselli, Richard John

AU - Graff Radford, Neill R

AU - Kramer, Joel H.

AU - Mendez, Mario F.

AU - Miller, Bruce L.

PY - 2007/10

Y1 - 2007/10

N2 - Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

AB - Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

KW - Clinical trials

KW - Frontotemporal lobar degeneration

KW - Longitudinal studies

KW - Primary progressive aphasia

UR - http://www.scopus.com/inward/record.url?scp=37349126255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349126255&partnerID=8YFLogxK

U2 - 10.1097/WAD.0b013e31815bf69d

DO - 10.1097/WAD.0b013e31815bf69d

M3 - Article

VL - 21

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 4

ER -